Nicox selects dose of blepharitis treatment to develop
Nicox plans to advance a once-daily blepharitis treatment candidate for consideration for a phase 2b clinical trial, the company announced in a press release.
NCX 4251 0.1% administered either once daily (10 patients) or twice daily (10 patients) for 14 days reduced eyelid redness, eyelid debris and eyelid discomfort when compared with placebo in the Danube first-in-human trial.
The ophthalmic suspension of fluticasone propionate nanocrystals is under study for treatment of the eyelid margin in acute exacerbations of blepharitis. The treatment also “demonstrated promising efficacy” in reducing signs and symptoms of dry eye disease, according to the release.
“We are also pleased by NCX 4251’s encouraging trends in the reduction of the signs and symptoms of dry eye disease, an important market in which NCX 4251 may have a benefit for treatment of the acute exacerbations of dry eye disease and as an induction therapy prior to the initiation of chronic dry eye treatment. We plan to discuss next steps for NCX 4251 with the U.S. FDA early next year and to secure the financial resources to accelerate its development,” Thomas Navratil, PhD, executive vice president and head of development at Nicox, said.